Clinical Trials on Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Finland

Total 51 results

CSL Behring

Completed

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy

Poland, France, Germany, Belgium, Finland
CSL Behring
ICON Clinical Research

Completed

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Polyradiculoneuropathy | Chronic Inflammatory Demyelinating Polyneuropathy

United States, Australia, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Spain, United Kingdom
Immunovant Sciences GmbH

Recruiting

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Chronic Inflammatory Demyelinating Polyneuropathy

United States, Italy, Norway, Greece, Poland, Sweden, Argentina, Belgium, Denmark, Finland, Germany, Portugal, Romania, Slovakia, Spain, Bulgaria, Korea, Republic of, United Kingdom, Brazil, Serbia
Turku University Hospital

Active, not recruiting

Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis (PROMS)

Multiple Sclerosis

Finland
Turku University Hospital

Completed

Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis (ROMUS)

Multiple Sclerosis | Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting

Finland
Turku University Hospital
Helsinki University Central Hospital; Päijänne Tavastia Central Hospital

Recruiting

Fecal Microbiota Transplantation and Newly Diagnosed Ulcerative Colitis (UC) (FinUC)

Ulcerative Colitis

Finland
Pfizer

Completed

This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.

Ulcerative Colitis

Finland
Turku University Hospital

Withdrawn

Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

Ulcerative Colitis

Finland
Joint Authority for Päijät-Häme Social and Health...
Helsinki University Central Hospital; University of Helsinki

Unknown

Fecal Transplantation in Ulcerative Colitis (FMT-CU)

Ulcerative Colitis

Finland
Eli Lilly and Company
BioMS Technology Corp.

Completed

A Study for Patients With Secondary Progressive Multiple Sclerosis (MAESTRO-01)

Secondary Progressive Multiple Sclerosis

Canada, Estonia, Denmark, Finland, Germany, Latvia, Netherlands, Spain, Sweden, United Kingdom
Eli Lilly and Company
BioMS Technology Corp.

Terminated

A Study for Patients With Multiple Sclerosis (MAESTRO-02)

Secondary Progressive Multiple Sclerosis

Canada, Estonia, Denmark, Finland, Latvia, Spain, Sweden, United Kingdom, Germany, Netherlands
Children's Hospital Medical Center, Cincinnati
Crohn's and Colitis Foundation

Completed

Anti-TNF Therapy for Refractory Colitis in Hospitalized Children (ARCH)

Colitis, Ulcerative | Bowel Diseases, Inflammatory

United States, Canada
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, Hungary, Brazil, Finland, Italy, Germany, Romania, Lithuania, France, Greece, Peru, Portugal, Spain, Switzerland, Bulgaria, Ukraine, Israel, Poland, Austria, New Zealand, Netherlands, Belgium, Mexico, United... and more
Genentech, Inc.

No longer available

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis

United States
Eli Lilly and Company

Recruiting

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-URGE)

Ulcerative Colitis | Ulcerative Colitis Chronic

United Kingdom, United States, Poland, Czechia, Hungary, Italy, France, Slovakia, Germany, Belgium
Novartis Pharmaceuticals

Completed

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Secondary Progressive Multiple Sclerosis

China, Germany, United States, Romania, Italy, Austria, Belgium, Czechia, Spain, Australia, Canada, France, Israel, Switzerland, Bulgaria, Hungary, Netherlands, United Kingdom, Estonia, Latvia, Lithuania, Russian Federation, Turkey, J... and more
Novartis Pharmaceuticals

Terminated

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. (INFORMS)

Primary Progressive Multiple Sclerosis

United States, Belgium, Poland, Germany, Hungary, Turkey, Spain, Australia, Canada, Czechia, Switzerland, United Kingdom, Netherlands, France, Italy, Denmark, Finland, Sweden
Shaare Zedek Medical Center

Completed

Manipulating the Microbiome in IBD by Antibiotics and FMT (FMT)

Exacerbation of Ulcerative Colitis | Ulcerative Colitis, Active Severe | Crohn's Colitis

Israel, Italy, Canada, Finland, Poland, Spain
Biogen

Terminated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Secondary Progressive Multiple Sclerosis

United States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
C. R. Bard

Terminated

The Pristine Post-Market Study

End Stage Renal Disease | Kidney Failure, Chronic | Hemodialysis Access Failure | Hemodialysis Complication | Central Venous Catheter Related Bloodstream Infection | Hemodialysis Catheter Infection

United States
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
Groupe d'Etude Therapeutique des Affections Inflammatoires...

Completed

Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis (CYSIF)

Ulcerative Colitis | Steroid Refractory

France, Spain, Belgium, Finland, Italy
Bausch Health Americas, Inc.

Completed

Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis

Ulcerative Colitis | Inflammatory Bowel Disease

United States
Bausch Health Americas, Inc.

Completed

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

Ulcerative Colitis | Inflammatory Bowel Disease

United States
Ferring Pharmaceuticals

Completed

Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission

Ulcerative Colitis

Sweden, Netherlands, Denmark, Belgium, Finland, Czech Republic, Germany, Norway
OMNI Medical Services, LLC
OMNI Medical Services Inc

Recruiting

Outcomes Mandate National Integration With Cannabis as Medicine (OMNI-Can)

Depression | COVID-19 | Epilepsy | Multiple Sclerosis | Glaucoma | Cancer | Covid19 | Chronic Pain | Parkinson Disease | Inflammatory Bowel Diseases | Hepatitis C | Insomnia | HIV/AIDS | Amyotrophic Lateral Sclerosis | Fibromyalgia | Anxiety | Bipolar Disorder | Seizures | Crohn Disease | Traumatic Brain Injury | Ulcerative Colitis | Sickle... and other conditions

United States
Centocor, Inc.

Completed

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Canada, Netherlands, Denmark
Connecticut Children's Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Predicting Response to Standardized Pediatric Colitis Therapy (PROTECT)

Ulcerative Colitis

United States, Canada
Warner Chilcott

Terminated

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis (CAMPIII)

Ulcerative Colitis

United States, Canada, Croatia, Russian Federation, Poland, Romania
Pfizer

Recruiting

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Israel, Poland, Canada, Japan, Belgium, Spain, Hungary, Finland, France, Australia, United Kingdom, Germany, Italy, Sweden, Netherlands, Slovakia
Shire

Completed

Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)

Ulcerative Colitis

United States
Warner Chilcott

Completed

Fecal Biomarker Study for Patients With Ulcerative Colitis

Ulcerative Colitis

United States
Bristol-Myers Squibb

Completed

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

Colitis, Ulcerative

Australia, United States, Canada, France, Mexico, Austria, Italy, Netherlands, Belgium, Germany, Brazil, Hungary, South Africa, Poland
Millennium Pharmaceuticals, Inc.

Completed

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis (GEMINI I)

Ulcerative Colitis

United States, Canada, Puerto Rico
Bausch Health Americas, Inc.

Completed

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Ulcerative Colitis

United States, Canada, India, Mexico
Merck Sharp & Dohme LLC
PPD, Part of Thermo Fisher Scientific

Recruiting

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Ulcerative Colitis

United States, Israel, Japan, Korea, Republic of, Switzerland, Chile, Dominican Republic, Canada, Netherlands
Janssen Research & Development, LLC
Janssen Biologics BV

Completed

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

Ulcerative Colitis

United States, France, United Kingdom, Belgium, Switzerland, Israel, Canada, Australia, Netherlands, New Zealand, Austria, Germany, Denmark, Czechia, Argentina
Bristol-Myers Squibb

Recruiting

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Colitis, Ulcerative

United States, United Kingdom
Amgen

Recruiting

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Taiwan, Germany, Spain, Turkey, Greece, Japan, Switzerland, Denmark, Korea, Republic of, Austria, Italy, Netherlands, Poland, Romania, Belgium, Argentina, Bulgaria, Czechia, Finland, Hungary, Mexico, Latvia, France, Canada, Slovaki...
Pfizer

Completed

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

Korea, Republic of, United States, United Kingdom, Australia, Austria, Denmark, Canada, Israel, Germany, Belgium, Taiwan, Latvia, Spain, Poland, New Zealand, Hungary, Netherlands, France, Estonia, Serbia, South Africa, Slovakia, Cro... and more
Shire

Terminated

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Hungary, Portugal, Turkey, Belgium, Bulgaria, New Zealand, Argentina, Greece, Bosnia and Herzegovina, Colombia, Estonia, Japan, Mexico, Slovakia, Ukraine, Ireland, Canada, Switzer...
Pfizer

Completed

Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

United States, Spain, Canada, Denmark, France, Australia, Belgium, Korea, Republic of, Hungary, Israel, Germany, Slovakia, Taiwan, Netherlands, Poland, New Zealand, United Kingdom, Japan, Austria, Estonia, Czechia, South Africa, Ukr... and more
Warner Chilcott

Completed

A Comparison of Once a Day Dose Compared to 2 Doses/Day

Ulcerative Colitis

United States, Canada, Puerto Rico
Shire

Completed

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)

Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
Eli Lilly and Company

Active, not recruiting

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Ulcerative Colitis

Spain, United States, China, Australia, Austria, Belgium, France, Italy, United Kingdom, Japan, Hungary, India, Serbia, Taiwan, Russian Federation, Canada, Korea, Republic of, Switzerland, Argentina, Israel, Latvia, Poland, Ukraine, D... and more
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis (U-Accomplish)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AbbVie

Active, not recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic... and more
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea,... and more
AbbVie

Active, not recruiting

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Australia, Austria, Belgium, Canada, Croatia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Puerto Rico, Spain, Sweden, United Kingdom
Shire

Completed

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Crohn's Disease | Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more

Clinical Trials on Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations